Federal Vaccine Committee Faces Controversy Over Hepatitis B Shots for Newborns

Mon Dec 15 2025 07:36:20 GMT+0200 (Eastern European Standard Time)

A U.S. federal committee is set to debate the Hepatitis B vaccine schedule for newborns, potentially impacting public health recommendations and igniting a controversy amidst differing expert opinions.

The Advisory Committee on Immunization Practices (ACIP) is expected to review its long-standing recommendation for administering the Hepatitis B vaccine to newborns within 24 hours of birth. The discussions come in light of a proposed shift in policy endorsed by Health Secretary Robert F. Kennedy Jr., sparking concerns among health professionals about potential negative outcomes for infant health. The American Academy of Pediatrics continues to advocate for the immediate administration of the vaccine, citing public health successes in reducing infections and deaths. As the discussion unfolds, reactions from political leaders and physicians raise alarms over the implications of delaying vaccinations.

Federal Vaccine Committee Faces Controversy Over Hepatitis B Shots for Newborns

NEW YORK (AP) — A federal vaccine advisory committee this week is expected to discuss whether newborns should still receive the hepatitis B vaccine — the first shot identified as preventive against cancer.

Current health recommendations suggest that all infants be vaccinated against the virus in their first day of life, yet U.S. Health Secretary Robert F. Kennedy Jr.'s committee is poised to alter this, challenging established public health advice.

The American Academy of Pediatrics (AAP), however, maintains that infants should still receive the vaccine at birth. Dr. Sean O’Leary of the AAP emphasized, “We are going to continue to recommend it because it saves lives.”

The Severity of Hepatitis B

Hepatitis B is a serious liver infection that can lead to chronic issues such as liver failure and cancer, particularly affecting infants and children. Current estimates indicate that around 2.4 million individuals in the U.S. are infected, with many unaware.

If left untreated, about 90% of infants infected with Hepatitis B will develop chronic infections, underscoring the importance of prompt vaccination.

Historical Context of the Vaccination Recommendations

Vaccination against Hepatitis B has been advised since 1991, initially recommending a dose immediately at birth. The rationale behind this guidance is to reduce the risk, especially given that the virus can be transmitted from an infected mother to her child, along with concerns about untested or inaccurately tested expectant mothers.

Over the past three decades, the vaccination milestone has been linked to a significant reduction in infections among children, dropping from approximately 18,000 cases annually to about 2,200.

Upcoming Discussions and Potential Changes

The upcoming meeting may evaluate changing the current practice, which could result in a delay of initial vaccinations. This has raised significant concern, with health professionals warning that postponing vaccinations could lead to increased infections and mortality rates among children.

Some committee members have expressed uncertainty about whether the recommendation is based on safety data or a response to parental concerns about early medical interventions. Calls for continued vaccination protocols have been echoed by politicians and medical experts alike, as public health organizations fear that any delays could confuse and alarm parents.

Senator Patty Murray, for instance, condemned the potential changes, labeling them as “heartless” and foreseeing dire consequences for infant health.

As the committee convenes, the discussions are set not only to address the immediate vaccination policies but to analyze the broader implications for public trust in immunization.